Capricor resumes DMD trial, will seek funding

Capricor Therapeutics Inc. (NASDAQ:CAPR) resumed dosing in the Phase II HOPE-2 trial of IV CAP-1002 for Duchenne muscular dystrophy (DMD). In December, the company placed a hold on the trial to investigate a severe allergic reaction that occurred in a patient during CAP-1002 infusion (see "Capricor Places DMD Trial on Hold").

Following the investigation, the company said the patient may have been allergic to something in the product and plans to begin a premedication strategy to help prevent additional patient reactions...